Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases
BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively wit...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , |
| Format: | article |
| Published: |
2007
|
| Online Access: | http://hdl.handle.net/10725/2578 http://dx.doi.org/10.1002/cncr.23099 https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513458650742784 |
|---|---|
| author | Ribero, David |
| author2 | Wang, Huamin Donadon, Matteo Zorzi, Daria Thomas, Melanie B. Eng, Cathy Chang, David Z. Curley, Steven A. Abdalla, Eddie K. Ellis, Lee Vauthey, Nicolas |
| author2_role | author author author author author author author author author author |
| author_facet | Ribero, David Wang, Huamin Donadon, Matteo Zorzi, Daria Thomas, Melanie B. Eng, Cathy Chang, David Z. Curley, Steven A. Abdalla, Eddie K. Ellis, Lee Vauthey, Nicolas |
| author_role | author |
| dc.creator.none.fl_str_mv | Ribero, David Wang, Huamin Donadon, Matteo Zorzi, Daria Thomas, Melanie B. Eng, Cathy Chang, David Z. Curley, Steven A. Abdalla, Eddie K. Ellis, Lee Vauthey, Nicolas |
| dc.date.none.fl_str_mv | 2007 2007-10-24 2015-11-16T10:54:58Z 2015-11-16T10:54:58Z |
| dc.identifier.none.fl_str_mv | 0008-543X http://hdl.handle.net/10725/2578 http://dx.doi.org/10.1002/cncr.23099 Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., ... & Vauthey, J. N. (2007). Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases. Cancer, 110(12), 2761-2767. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Cancer |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had <25% residual viable tumor cells (45% vs 23%; P = .02). However, the addition of bevacizumab to 5FU/OX did not appear to increase the incidence of complete pathologic response (11.3% vs 11.6%; P = .59). The incidence and severity of sinusoidal dilation was lower in patients treated with bevacizumab than in those treated with 5FU/OX only (any grade: 27.4% vs 53.5%; moderate or severe: 8.1% vs 27.9%; both P < .01). CONCLUSIONS. In patients treated with 5FU/OX chemotherapy, bevacizumab improves the pathologic response, as demonstrated by a reduction of the degree of tumor viability, and reduces the incidence and severity of hepatic injury. This retrospective study provides additional evidence supporting the use of bevacizumab in combination with 5FU/OX for CLM. Cancer 2007. © 2007 American Cancer Society. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_1d7f9f2ed2d6a05649d804758cc86fc0 |
| identifier_str_mv | 0008-543X Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., ... & Vauthey, J. N. (2007). Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases. Cancer, 110(12), 2761-2767. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/2578 |
| publishDate | 2007 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver MetastasesRibero, DavidWang, HuaminDonadon, MatteoZorzi, DariaThomas, Melanie B.Eng, CathyChang, David Z.Curley, Steven A.Abdalla, Eddie K.Ellis, LeeVauthey, NicolasBACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had <25% residual viable tumor cells (45% vs 23%; P = .02). However, the addition of bevacizumab to 5FU/OX did not appear to increase the incidence of complete pathologic response (11.3% vs 11.6%; P = .59). The incidence and severity of sinusoidal dilation was lower in patients treated with bevacizumab than in those treated with 5FU/OX only (any grade: 27.4% vs 53.5%; moderate or severe: 8.1% vs 27.9%; both P < .01). CONCLUSIONS. In patients treated with 5FU/OX chemotherapy, bevacizumab improves the pathologic response, as demonstrated by a reduction of the degree of tumor viability, and reduces the incidence and severity of hepatic injury. This retrospective study provides additional evidence supporting the use of bevacizumab in combination with 5FU/OX for CLM. Cancer 2007. © 2007 American Cancer Society.PublishedN/A2015-11-16T10:54:58Z2015-11-16T10:54:58Z20072007-10-24Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0008-543Xhttp://hdl.handle.net/10725/2578http://dx.doi.org/10.1002/cncr.23099Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., ... & Vauthey, J. N. (2007). Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases. Cancer, 110(12), 2761-2767.https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099enCancerinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/25782025-10-22T09:56:19Z |
| spellingShingle | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases Ribero, David |
| status_str | publishedVersion |
| title | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| title_full | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| title_fullStr | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| title_full_unstemmed | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| title_short | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| title_sort | Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases |
| url | http://hdl.handle.net/10725/2578 http://dx.doi.org/10.1002/cncr.23099 https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099 |